方法：选取我院2012-07/2015-06确诊为慢性泪囊炎的患者297例328眼，其中单眼266例，双眼31例，随机分为治疗组166例166眼，对照组162例162眼(如为双眼患病者，1眼纳入治疗组，1眼纳入对照组)，均采用鼻内镜下鼻腔泪囊造孔联合鼻泪管引流支架置入的手术方式，治疗组局部应用0.2mg/mL丝裂霉素C，对照组则不使用； 术后随访3～36mo，观察患者临床疗效及安全性。

结果：治疗组166眼，治愈121眼，好转37眼，无效8眼，总有效率95.18%； 对照组162眼，治愈103眼，好转36眼，无效23眼，总有效率85.80%； 两组之间的差异有统计学意义(P<0.05)。

结论：丝裂霉素C应用于鼻内镜下鼻腔泪囊造孔术治疗慢性泪囊炎，组织损伤小，能有效减少术后造孔处瘢痕粘连及肉芽组织增生，提高手术成功率，是一种简便、安全、有效的治疗方式。

METHODS:Selecting 297 patients(328 eyes)who were diagnosed as chronic dacryocystitis from July 2012 to June 2015 in our hospital, in which 266 patients were monocular and 31 were binocular. And then dividing them into two groups, 166 patients(166 eyes)in treatment group,and there were 162 patients(162 eyes)in control group. If the patient was binocular, each eye was selected in treatment group or control group randomly. The surgical procedures of nasal endoscopic dacryocystorhinostomy combined with nasolacrimal duct stent placement, were used in both groups, and MMC with the concentration of 0.2mg/mL was applied topically to the treatment group, while the control group was treated without MMC. All cases were followed up for 3 to 36mo, observed for clinical effect and safety.

RESULTS:One hundred and twenty-one eyes were cured, 37 were improved and 8 were failed in the treatment group of 166 eyes, total effective rate was 95.18%. While in the control group, 103 eyes were cured, 36 were improved and 23 were failed in 162 eyes, total effective rate was 85.80%. The difference between the two groups was statistically significant(P<0.05).

CONCLUSION: MMC applied to nasal endoscopic dacryocystorhinostomy for chronic dacryocystitis allows less tissue injury, effectively reduces cicatricial adhesion and hyperplasia of granulation tissue after operations on nasal cavity and enhance the success rate of the operations, which is a simple, safe and effective treatment.